![conference banner](/images/conference-banner.jpeg)
[1]
Singh K, Kumar N, Kumar A, Kumar A, Shaju AR. Sympathetic storm or cytokine storm: A diagnostic dilemma in patient of traumatic brain injury with COVID 19. Acta Neurol Taiwan 2021; 30(2): 78-80.
[PMID: 34549393]
[PMID: 34549393]
[2]
Dinsmore J. Traumatic brain injury: An evidence-based review of management. Contin Educ Anaesth Crit Care Pain 2013; 13(6): 189-95.
[http://dx.doi.org/10.1093/bjaceaccp/mkt010]
[http://dx.doi.org/10.1093/bjaceaccp/mkt010]
[5]
Meyfroidt G, Baguley IJ, Menon DK. Paroxysmal sympathetic hyperactivity: The storm after acute brain injury. Lancet Neurol 2017; 16(9): 721-9.
[http://dx.doi.org/10.1016/S1474-4422(17)30259-4] [PMID: 28816118]
[http://dx.doi.org/10.1016/S1474-4422(17)30259-4] [PMID: 28816118]
[6]
Bueno González AM, Corcobado Marquez MC, Portilla Botelho M, Ambrós Checa A. Diagnostic challenge of paroxysmal sympathetic hyperactivity (PSH) associated with diffuse axonal injury (DAI) in head trauma. Springerplus 2014; 3(1): 752.
[http://dx.doi.org/10.1186/2193-1801-3-752] [PMID: 26034702]
[http://dx.doi.org/10.1186/2193-1801-3-752] [PMID: 26034702]
[7]
Khalid F, Yang GL, McGuire JL, et al. Autonomic dysfunction following traumatic brain injury: Translational insights. Neurosurg Focus 2019; 47(5)E8
[http://dx.doi.org/10.3171/2019.8.FOCUS19517] [PMID: 31675718]
[http://dx.doi.org/10.3171/2019.8.FOCUS19517] [PMID: 31675718]
[8]
Totikov A, Boltzmann M, Schmidt SB, Rollnik JD. Influence of paroxysmal sympathetic hyperactivity (PSH) on the functional outcome of neurological early rehabilitation patients: A case control study. BMC Neurol 2019; 19(1): 162.
[http://dx.doi.org/10.1186/s12883-019-1399-y] [PMID: 31315589]
[http://dx.doi.org/10.1186/s12883-019-1399-y] [PMID: 31315589]
[9]
Rabaan AA, Al-Ahmed SH, Muhammad J, et al. Role of inflammatory cytokines in COVID-19 patients: A review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines (Basel) 2021; 9(5): 436.
[http://dx.doi.org/10.3390/vaccines9050436] [PMID: 33946736]
[http://dx.doi.org/10.3390/vaccines9050436] [PMID: 33946736]
[10]
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 2020; 80(6): 607-13.
[http://dx.doi.org/10.1016/j.jinf.2020.03.037] [PMID: 32283152]
[http://dx.doi.org/10.1016/j.jinf.2020.03.037] [PMID: 32283152]
[11]
Porzionato A, Emmi A, Barbon S, et al. Sympathetic activation: A potential link between comorbidities and COVID-19. FEBS J 2020; 287(17): 3681-8.
[http://dx.doi.org/10.1111/febs.15481] [PMID: 32779891]
[http://dx.doi.org/10.1111/febs.15481] [PMID: 32779891]